Renalytix Plc (RNLXY)

Market Cap	44.15M +6.8%
Revenue (ttm)	3.00M
Net Income	-14.20M
EPS	-1.75
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,597
Open	3.750
Previous Close	3.700
Day's Range	3.700 - 3.750
52-Week Range	0.999 - 5.550
Beta	1.55
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 24, 2026

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, cl...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Employees: 46
• Stock Exchange: OTCMKTS
• Ticker Symbol: RNLXY

Financial Performance

In fiscal year 2026, Renalytix's revenue was $3.00 million, a change of 0.00% compared to the previous year's $3.00 million. Losses were -$14.20 million, -30.39% less than in 2025.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Nov 10, 2026

Data Sources Report a data error